Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including ...

Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

Biodesix, Inc has expanded its long-standing collaboration with Bio-Rad Laboratories to co-develop and clinically validate ...

Expert consensus predicts integration of CTC testing into routine clinical practice within 5 years  2.    CTCs provide distinct and impactful information that is not captured by circulating tumour DNA ...

Tissue-engineered and chip-based models are changing how scientists study early cancer, leading to more accurate and humane ...